The benefits and risks of antidepressant drugs

Human Psychopharmacology: Clinical and Experimental

Volumn 3, Issue 2, 1988, Pages 73-86

  Pinder, R M ^a  

^a NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MIANSERIN; NOMIFENSINE; ZIMELDINE;

ADVERSE DRUG REACTION; CARDIOVASCULAR RESPONSE; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG OVERDOSE; EPILEPSY; HUMAN; PSYCHOLOGICAL ASPECT; REVIEW;

EID: 0023909513     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.470030203     Document Type: Review

References (66)

1. Agranulocytosis associated with tricyclics
2. Therapeutic effects of serotonin uptake inhibitors in depression
3. Mortality in depressed patients treated with electroconvulsive therapy and antidepressants
4. A two‐year naturalistic follow‐up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both
5. Antidepressant drugs
6. Management of depression in general practice
7. And a small dose of an antidepressant might help
8. Fatal toxicity of antidepressant drugs in overdose
9. One hundred cases of acute intoxication with mianserin hydrochloride
10. Second generation antidepressants: A comparative review
11. Circumstances surrounding deaths from accidental poisoning
12. Clinical features and management of self‐poisoning with newer antidepressants
13. Fatal tricyclic antidepressant poisoning
14. The problem of tricyclic antidepressant poisoning
15. Adverse reactions to antidepressants
16. Withdrawal of nomifensin
17. Drugs used in the treatment of depression
18. Antidepressants and seizures: epidemiological and clinical aspects
19. Which depressions respond to placebo?
20. Tricyclic antidepressant overdose
21. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review
22. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomised, doubleblind, controlled trial
23. Suicide among primary affective disorders
24. Clinical aspects of tricyclic antidepressant poisoning
25. Incidence of seizures with tricyclic and tetracyclic antidepressants
26. Prediction of the course and outcome of depression
27. The timing, specificity and clinical prediction of tricyclic drug effects in depression
28. Treatment received by depressed patients
29. Clinical pharmacology of imipramine and related antidepresant compounds
30. Effects of self poisoning with maprotiline
31. Poisoning with antidepressive drugs: A five‐year retrospective study
32. Toxicity of antidepressants
33. Postmarketing surveillance: how many patients?
34. Amoxapine overdosage, seizures and fatalities
35. Prophylactic effect of continuous treatment with antidepressants
36. Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine
37. Medicines evaluation and monitoring group: a follow‐up study of cardiac patients receiving amitriptyline
38. Do some antidepressants promote suicide?
39. The prevention of recurrent suicidal acts
40. The efficacy of antidepressant drugs
41. Antidepressants and heart disease
42. The present status of monomamine oxidase inhibitors
43. Tricyclic antidepressant poisoning: management of arrhythmias
44. Antidepressant drugs of the future
45. 2‐adrenoceptor antagonists as antidepressants
46. Viloxazine: A review of its pharmacological properties and therapeutic efficacy in depressive illness
47. Drugs prescribed for self poisoners
48. Continuation drug therapy for major depressive episodes: how long should it be maintained?
49. Acute poisoning with antidepressants and lithium
50. Monoamine oxidase inhibitors. A review of their antidepressant effectiveness
51. Duration of antidepressant drug treatment. What is an adequate trial?
52. Baseline characteristics of 10‐day placebo washout responders in antidepressant trials
53. A statistical review of controlled trials of imipramine and placebo in the treatment of depressive illness
54. Chronic mood disorders in depressive outpatients
55. Mortality in psychiatric hospitals in Norway 1950–74
56. Why the excess mortality from psychiatric illness?
57. Incidence of self poisoning in patients prescribed psychotropic drugs
58. Orthostatic hypotension and antidepressant pharmacotherapy
59. Premature deaths in schizophrenia and affective disorders
60. Drug treatment of psychiatric patients in general practice
61. Drug‐induced aplastic anaemia and agranlocytosis. Incidence and mechanisms
62. Review of clinical studies with mianserin
63. Relative toxicity of cyclic antidepressants
64. Recognition and treatment of depression in family practice